During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.
Zev A. Wainberg, MD, professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, provides expert insight on how gastric treatment will evolve over the next 5 years.
0:08 |That's a good question. I think gastric cancer is going to get increasingly subdivided into smaller groups. I think we already know now, that HER2, MSS, or MSI should stay, And CPS you know, those are, I'd say validated biomarkers. We have a few more on the way hopefully with FGFR2B, and also claudin18, and hopefully others beyond that.
0:31 | So, I think, you know, what we'll expect to see over the next few years is more some dividing of the of the pie, which allows us hopefully to find better outcomes are also going to see better exploration of these drugs probably and beyond frontline settings and into earlier spaces such as adjuvant or neoadjuvant, gastric cancer. So, we do have hopefully a good plan for the next few years to develop new drugs and this, you know, terribly unmet need.